Standard BioTools
LAB
65 hedge funds and large institutions have $42.5M invested in Standard BioTools in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 25 closing their positions.
7.68% less ownership
Funds ownership: 56.8% → 49.12% (-7.7%)
24% less funds holding
Funds holding: 86 → 65 (-21)
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
39% less capital invested
Capital invested by funds: $70.2M → $42.5M (-$27.7M)
54% less call options, than puts
Call options by funds: $44K | Put options by funds: $96K
84% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 25
Top Buyers
| 1 |
JCP
Jennifer C. Price
|
+$921K |
| 2 |
Neuberger Berman Group
New York
|
+$600K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$600K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$245K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$210K |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.18M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.82M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$902K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$860K |
| 5 |
Millennium Management
New York
|
-$657K |
LAB Hedge Fund Activity: Q3 2022 in Review
65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2022, worth a combined $42.5M — down 39% from $70.2M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of LAB and 4 opened new positions — a net loss of 21 holders — while 28 trimmed existing stakes and 17 added.
The largest buyer was Jennifer C. Price, adding an estimated $921K. The largest seller was RA Capital Management, exiting entirely with an estimated $3.18M sold.
- 65 institutional investors held Standard BioTools (LAB) as of Q3 2022, down from 86 in Q2 2022.
- Funds reported $42.5M of Standard BioTools stock for Q3 2022, down 39% quarter-over-quarter.
- 4 funds opened new Standard BioTools positions in Q3 2022 and 25 closed out, a net change of -21 holders.
- The largest Standard BioTools buyer in Q3 2022 was Jennifer C. Price, an estimated $921K added.
- The largest Standard BioTools seller in Q3 2022 was RA Capital Management, an estimated $3.18M sold.
Based on aggregated 13F filings for Q3 2022.